Mylan receives generic approval for Lilly’s blockbuster 02-Sep-2019 By Ben Hargreaves US FDA updates Mylan’s ANDA to commercialize a generic of Lilly’s Alimta with a tentative approval, putting the company on course to enter the market in 2022.